CLDN18.2 antibodies and uses thereof
Patent Information
- Application Number
- JP2023532401
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-27
- Filing Date
- 2021-11-26
- Publication Date
- 2024-12-04
- Estimated Expiration
- 2041-11-26
AI Technical Summary
Current immunization procedures are unable to generate effective antibodies against CLDN18.2 due to high homology between human and mouse claudin 18.2 proteins, limiting targeted therapy options for gastric and pancreatic cancers.
Immunize C57 mice with a plasmid containing the full-length human claudin 18.2 gene, screen for murine antibodies using hybridoma fusion technology, and develop antibodies with specific CDR sequences (SEQ ID NOs: 1-12) that recognize CLDN18.2, creating chimeric antigen receptors (CARs) for targeted therapy.
The developed antibodies and CARs exhibit high specificity and efficacy in targeting and killing cancer cells expressing CLDN18.2, with minimal non-specific effects, and can be used for diagnostic and therapeutic applications.
Abstract
Description
[Technical Field]
[0001] Cross-reference of related applications This application claims priority to Chinese Patent Application No. 202011364033.6, filed with the China National Intellectual Property Administration on November 27, 2020, which is incorporated herein by reference in its entirety.
[0002] The present invention relates to the field of biotechnology. More specifically, the present invention relates to CLDN18.2 antibodies and their uses. More specifically, the present invention relates to antibodies, chimeric antigen receptors, immune cells, nucleic acid molecules, expression vectors, recombinant cells, pharmaceutical compositions, pharmaceutical uses, kits for detecting CLDN18.2, uses of kits for detecting CLDN18.2, and uses of screening antibodies. [Background technology]
[0003] Gastric cancer is the third leading cause of cancer-related death and is considered one of the most difficult cancers to cure worldwide. In patients with advanced or metastatic gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma, the median overall survival (mOS) is not greater than 10 months. While human epidermal growth factor receptor 2 (HER-2) targeted therapies and immune checkpoint inhibitors have offered good news for certain populations, finding other targets in advanced gastric cancer is absolutely essential.
[0004] Claudins are a family of proteins whose role is to maintain tight junctions that control the exchange of molecules between cells. They are widely distributed in gastric, pancreatic, and lung tissues and can be used to diagnose and treat related tissue diseases. The CLDN18.2 subtype is highly selective, specifically expressed in small amounts in gastric tissue and not in other normal tissues, and is expressed in large amounts in gastric cancer cells, pancreatic cancer cells, and other cancer cells. Therefore, it is an ideal target for oncological drug therapy, making CLDN18.2 specific for targeted therapy. Due to the high degree of homology between human and mouse claudin 18.2 proteins (homology is higher than 90%), conventional immunization procedures cannot produce effective immune antibodies. [Prior art documents] [Patent Documents]
[0005] [Patent Document 1] U.S. Patent No. 5,449,752 [Non-patent literature]
[0006] [Non-Patent Document 1] Chan et al., Fmoc Solid Phase Peptide Synthesis, Oxford University Press, Oxford, UK, 2000. [Non-Patent Document 2] Peptide and Protein Drug Analysis, edited by Reid, R., Marcel Dekker Inc., 2000 [Non-Patent Document 3] Epitope Mapping, Westwood et al. (eds.), Oxford University Press, Oxford, UK, 2001. [Non-Patent Document 4] Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd edition, Cold Spring Harbor Press, Cold Spring Harbor, New York, 2001. [Non-Patent Document 5] Ausubel et al., *Current Protocols in Molecular Biology*, Greene Publishing Associates and John Wiley & Sons, New York, 1994. [Overview of the project] [Problems that the invention aims to solve]
[0007] It can be understood that developing highly specific antibodies against CLDN18.2 would be extremely significant for the diagnosis and treatment of tumors. [Means for solving the problem]
[0008] To address the above issues, the inventors immunized C57 mice with claudin 18.2 gene knockout using a plasmid containing the full-length h-claudin 18.2 gene, and screened two anti-claudin 18.2 mouse antibodies with different affinity and binding epitopes through hybridoma fusion technology. The heavy and light chain variable regions of the two antibodies were obtained by gene sequencing. With the help of a linker, the light and heavy chain variable regions were linked in series to form a VL-linker-VH structure for various subsequent applications.
[0009] In a first aspect of the present invention, the present invention provides an antibody or an antigen-binding fragment thereof having the ability to specifically recognize CLDN18.2. According to one embodiment of the present invention, the antibody or the antigen-binding fragment thereof includes at least one CDR sequence selected from the CDR sequences of the light chain variable region: SEQ ID NOs: 1-3, SEQ ID NOs: 7-9, and the CDR sequences of the heavy chain variable region: SEQ ID NOs: 4-6, SEQ ID NOs: 10-12, or an amino acid sequence having at least 95% identity thereto. SQSLLNSGNQKNYL (SEQ ID NO: 1). YWAST (SEQ ID NO: 2). CQNDYSYPFTF (SEQ ID NO: 3). SQSLFNSGNQKNYL (SEQ ID NO: 7). YWAST (SEQ ID NO: 8). CQNDYSYPLTF (SEQ ID NO: 9). SGYTFTSYWM (SEQ ID NO: 4).<000008The CDR1, CDR2, and CDR3 sequences of the heavy chain variable region shown in SEQ ID NOs: 4, 5, and 6, respectively, or amino acid sequences having at least 95% identity with SEQ ID NOs: 4, 5, and 6, or The CDR1, CDR2, and CDR3 sequences of the heavy chain variable region shown in SEQ ID NOs. 10, 11, and 12, respectively, or amino acid sequences having at least 95% identity with SEQ ID NOs. 10, 11, and 12. Includes.
[0014] According to one embodiment of the present invention, compared to peptide E, the antibody or its antigen-binding fragment uses peptide A as the dominant epitope that specifically recognizes CLDN18.2, with the sequence of peptide E shown in SEQ ID NO: 14 and the sequence of peptide A shown in SEQ ID NO: 13. DLYNNPVTAVFNYQGLWRSC (Sequence ID 14). DQWSTQDLYNNPVTAVFNYQGC (Sequence ID 13).
[0015] According to one embodiment of the present invention, an antibody having any one of the sequences of SEQ ID NOs: 1-3 and SEQ ID NOs: 4-6 binds only to the epitope where peptide A is located, while an antibody having any one of the sequences of SEQ ID NOs: 7-9 and SEQ ID NOs: 10-12 can bind to a complex epitope consisting of peptides A and E, with peptide A being the dominant epitope.
[0016] According to one embodiment of the present invention, the antibody comprises at least one of a heavy chain framework region sequence and a light chain framework region sequence, and at least a portion of at least one of the heavy chain framework region sequence and the light chain framework region sequence is derived from at least one of a mouse antibody, a human antibody, a primate antibody, or a mutant thereof.
[0017] According to one embodiment of the present invention, the antibody has a light chain variable region having the amino acid sequence shown in either SEQ ID NO: 15 or SEQ ID NO: 16, and / or the antibody has a heavy chain variable region having the amino acid sequence shown in either SEQ ID NO: 17 or SEQ ID NO: 18. DIVMTQSPSSLSVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPFTFGSGTKLEIK(Sequence ID 15). DIVMTQSPSSLTVTAGEKVTMSCKSSQSLFNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYFCQNDYSYPLTFGAGTKLELR (Sequence ID 16). QVQLQQPGSELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGMIHPNSGSTNYNEKFKSKATLTVDKSSSTAYMQLSSLTSEDSAVYYCARRYYGSISPDYWGQGTTLTVSS(Sequence No. 17). EVQLQQSGPELVRPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLEWIGYINPNNGGTSYNQKFKGKATLTVNKSSSTAYMELRSLTSEDSAVYYCVTTRYLAVWGTGTTVTVSS(Sequence ID 18)
[0018] According to one embodiment of the present invention, the antibody has a light chain variable region having the amino acid sequence of SEQ ID NO: 15 and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 17.
[0019] According to one embodiment of the present invention, the antibody has a light chain variable region having the amino acid sequence of SEQ ID NO: 16 and a heavy chain variable region having the amino acid sequence of SEQ ID NO: 18.
[0020] According to one embodiment of the present invention, the antibody comprises at least one of a heavy chain constant region and a light chain constant region, and at least a portion of at least one of the heavy chain constant region and the light chain constant region is derived from at least one of a mouse antibody, a human antibody, a primate antibody, or a mutant thereof.
[0021] According to one embodiment of the present invention, both the light chain constant region and the heavy chain constant region of the antibody are derived from a mouse IgG antibody or a mutant thereof. According to the antibody of the embodiment of the present invention, both the light chain constant region and the heavy chain constant region of the antibody are derived from human IgG4, IgG3, or IgG1.
[0022] According to one embodiment of the present invention, the antibody has a light chain having the amino acid sequence shown in either SEQ ID NO: 19 or SEQ ID NO: 20: DIVMTQSPSSLTVTAGEKVTMSCKSSQSLFNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYFCQNDYSYPLTFGAGTKLELRRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC(Sequence ID 19). DIVMTQSPSSLSVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPFTFGSGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC(Sequence ID 20).
[0023] According to one embodiment of the present invention, the antibody has a heavy chain having the amino acid sequence shown in either SEQ ID NO: 21 or SEQ ID NO: 22: EVQLQQSGPELVRPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLEWIGYINPNNGGTSYNQKFKGKATLTVNKSSSTAYMELRSLTSEDSAVYYCVTTRYLAVWGTGTTVTVSS AKTTPPSVYPLAPGCGDTTGSSVTLGCLVKGYFPESVTVTWNSGSLSSSSVHTFPALLQSGLYTMSSSVTVPSSTWPSQTVTCSVAHPASSTTVDKKLEPSGPISTINPCPPCKEC HKCPAPNLEGGPSVFIFPPNIKDVLMISLTPKVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTIRVVSTLPIQHQDWMSGKEFKCKVNNKDLPSPIERTISKIKGLVRAPQVYILPPPAEQLSRKDVSLTCLVVGFNPGDISVEWTSNGHTEENYKDTAPVLDSDGSYFIYSKLNMKTSKWEKTDSFSCNVRHEGLKNYYLKKTISRSPGK(Sequence No. 21). QVQLQQPGSELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGMIHPNSGSTNYNEKFKSKATLTVDKSSSTAYMQLSSLTSEDSAVYYCARRYYGSISPDYWGQGTTLT VSSAKTTPPSVYPLAPGCGDTTGSSVTLGCLVKGYFPESVTVTWNSGSLSSSVHTFPALLQSGLYTMSSSVTVPSSTWPSQTVTCSVAHPASSTTVDKKLEPSGPISTINPCPPCK ECHKCPAPNLEGGPSVFIFPPNIKDVLMISLTPKVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTIRVVSTLPIQHQDWMSGKEFKCKVNNKDLPSPIERTISKIKGLVRAPQVYILPPPAEQLSRKDVSLTCLVVGFNPGDISVEWTSNGHTEENYKDTAPVLDSDGSYFIYSKLNMKTSKWEKTDSFSCNVRHEGLKNYYLKKTISRSPGK(Sequence ID 22).
[0024] According to one embodiment of the present invention, an antibody having a heavy chain with the amino acid sequence of SEQ ID NO: 21 and a light chain with the amino acid sequence of SEQ ID NO: 19 is an m1B6 antibody. An antibody having a heavy chain with the amino acid sequence of SEQ ID NO: 22 and a light chain with the amino acid sequence of SEQ ID NO: 20 is an m1E7 antibody.
[0025] According to one embodiment of the present invention, the antibody is a single-chain antibody, a chimeric antibody, a multimeric antibody, or a CDR-transplanted antibody.
[0026] According to one embodiment of the present invention, the antibody is a single-chain antibody, and the single-chain antibody has the amino acid sequence shown in either SEQ ID NO: 23 or SEQ ID NO: 24: DIVMTQSPSSLTVTAGEKVTMSCKSSQSLFNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYFCQNDYSYPLTFGAGTKLELRGGGGSGGGGSGGGGSEVQLQQSGPELVRPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLEWIGYINPNNGGTSYNQKFKGKATLTVNKSSSTAYMELRSLTSEDSAVYYCVTTRYLAVWGTGTTVTVSS(Sequence No. 23). DIVMTQSPSSLSVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPFTFGSGTKLEIKGGGGSGGGGSGGGGSQVQLQQPGSELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGMIHPNSGSTNYNEKFKSKATLTVDKSSSTAYMQLSSLTSEDSAVYYCARRYYGSISPDYWGQGTTLTVSS(Sequence No. 24).
[0027] According to one embodiment of the present invention, an antibody having the amino acid sequence of SEQ ID NO: 23 is called a 1B6 antibody, and an antibody having the amino acid sequence of SEQ ID NO: 24 is called a 1E7 antibody. Of these, antibodies having the amino acid sequences shown in SEQ ID NO: 23 and SEQ ID NO: 24 can be represented as VL-linker-VH from the N-terminus to the C-terminus. VL represents the light chain variable region, and VH represents the heavy chain variable region. The linker represents the connecting chain that links VL and VH.
[0028] According to one embodiment of the present invention, the antibodies may be chimeric antibodies 1B6 and 1E7, and the chimeric antibody 1B6 has a heavy chain of SEQ ID NO: 31 and a light chain of SEQ ID NO: 32. EVQLQQSGPELVRPGASVKMSCKASGYTFTDYNMHWVKQSHGKSLEWIGYINPNNGGTSYNQKFKGKATLTVNKSSSTAYMELRSLTSEDSAVYYCVTTRYLAVWGTGTTVTV SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ PREPQVYTLPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 31). DIVMTQSPSSLTVTAGEKVTMSCKSSQSLFNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYFCQNDYSYPLTFGAGTKLELRRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (Sequence ID 32).
[0029] Chimeric antibody 1E7 has the heavy chain of SEQ ID NO: 33 and the light chain of SEQ ID NO: 34. QVQLQQPGSELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGMIHPNSGSTNYNEKFKSKATLTVDKSSSTAYMQLSSLTSEDSAVYYCARRYYGSISPDYWGQGTT LTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCP PCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (Sequence ID 33). DIVMTQSPSSLSVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPFTFGSGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (Sequence ID 34)
[0030] According to one embodiment of the present invention, the antigen-binding fragment comprises at least one of the following: a Fab fragment, a (Fab)2 fragment, an scFv-Fc fusion protein, an scFv-Fv fusion protein, an Fv fragment, and a minimal recognition unit.
[0031] In a second aspect of the present invention, the present invention provides a chimeric antigen receptor. According to one embodiment of the present invention, the chimeric antigen receptor comprises an extracellular region, the extracellular region comprising a heavy chain variable region and a light chain variable region of a single-chain antibody, the light chain variable region and the heavy chain variable region being determined according to the antibody or its antigen-binding fragment provided in the first aspect of the present invention. According to one embodiment of the present invention, the chimeric antigen receptor can be used to prepare drugs that perform biological roles based on the antigen-recognizing ability of the antibody.
[0032] According to one embodiment of the present invention, the chimeric antigen receptor further comprises a transmembrane region and an intracellular region, the transmembrane region comprising a CD8 transmembrane region, and the intracellular region comprising an ICOS intracellular segment, 4-1BB, and a CD3ζ chain.
[0033] According to one embodiment of the present invention, the N-terminus of the ICOS intracellular segment is connected to the C-terminus of the CD8 transmembrane domain, the C-terminus of the ICOS intracellular segment is connected to the N-terminus of the 4-1BB intracellular segment, and the C-terminus of the 4-1BB intracellular segment is connected to the N-terminus of the CD3ζ chain. The inventors found that the transmembrane domain and intracellular segment of the immunostimulator in the chimeric antigen receptor are connected in the above sequence, the obtained chimeric antigen receptor has a high expression titer in viruses, immune cells expressing the chimeric antigen receptor have a significant specific killing effect against tumor cells expressing CLDN18.2, and nonspecific killing and cellular inflammatory factor responses were weak.
[0034] According to one embodiment of the present invention, the structure of the chimeric antigen receptor is signal peptide-anti-claudin 18.2 scfv-CD8 hinge+CD8™-ICOS-4-1BB-CD3ζ, and the amino acid sequence of anti-claudin 18.2 scfv is shown in either SEQ ID NO: 23 or SEQ ID NO: 24.
[0035] According to one embodiment of the present invention, the amino acid sequence of the signal peptide of the chimeric antigen receptor is shown in SEQ ID NO: 25. MGVKVLFALICIAVAEA (Sequence ID 25)
[0036] According to one embodiment of the present invention, the amino acid sequence of the CD8 hinge of the chimeric antigen receptor is shown in SEQ ID NO: 26. TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD (Sequence ID 26)
[0037] According to one embodiment of the present invention, the amino acid sequence of the chimeric antigen receptor CD8TM is shown in SEQ ID NO: 27. IYIWAPLAGTCGVLLLSLVITLYC (Sequence ID 27)
[0038] According to one embodiment of the present invention, the amino acid sequence of the chimeric antigen receptor ICOS is shown in SEQ ID NO: 28. CWLTKKKYSSSVHDPNGEYMFMRAVNTAKKSRLTDVTL (Sequence ID 28)
[0039] According to one embodiment of the present invention, the amino acid sequence of the 4-1BB of the chimeric antigen receptor is shown in SEQ ID NO: 29. KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL (Sequence ID 29)
[0040] According to one embodiment of the present invention, the amino acid sequence of the chimeric antigen receptor CD3ζ is shown in SEQ ID NO: 30. RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR(Sequence ID 30)
[0041] In a third aspect of the present invention, the present invention provides immune cells. According to one embodiment of the present invention, the immune cells express the chimeric antigen receptor proposed in the second aspect of the present invention. The immune cells according to the embodiments of the present invention have good killing effects in vivo and in vitro.
[0042] According to one embodiment of the present invention, the aforementioned nucleic acid immune cells may further include the following additional technical features:
[0043] According to one embodiment of the present invention, the immune cells include at least one of T lymphocytes, DC cells, NK cells, and NKT lymphocytes. The immune cells according to the embodiments of the present invention recognize and kill target proteins, cells, tissues, organs, etc., using the antibody provided in the first embodiment of the present invention or the chimeric antigen receptor provided in the second embodiment of the present invention, and then perform biological functions.
[0044] In a fourth aspect of the present invention, the present invention provides a nucleic acid molecule. According to one embodiment of the present invention, the nucleic acid molecule encodes an antibody or antigen-binding fragment thereof provided in the first aspect of the present invention, or a chimeric antigen receptor provided in the second aspect of the present invention. The antibody or antigen-binding fragment encoded by the nucleic acid molecule according to the embodiment of the present invention can specifically target and bind to CLDN18.2 and has high antigen-binding activity.
[0045] According to one embodiment of the present invention, the nucleic acid molecule may further include the following additional technical features:
[0046] According to one embodiment of the present invention, the nucleic acid molecule is DNA.
[0047] In a fifth aspect of the present invention, the present invention provides an expression vector. According to one embodiment of the present invention, the expression vector has the nucleic acid molecule provided in the fourth aspect of the present invention. After introducing the expression vector according to an embodiment of the present invention into a suitable recipient cell, it can effectively achieve the expression of the aforementioned antibody or its antigen-binding fragment that specifically recognizes CLDN18.2 under the mediation of a regulatory system, thereby enabling the acquisition of large quantities of the antibody or antigen-binding fragment in vitro.
[0048] According to one embodiment of the present invention, the nucleic acid molecule may further include the following additional technical features:
[0049] According to one embodiment of the present invention, the expression vector is a eukaryotic expression vector or a virus. Preferably, the virus is a lentivirus. According to one embodiment of the present invention, the eukaryotic expression vector may be a CHO cell.
[0050] In a sixth aspect of the present invention, the present invention provides recombinant cells. According to one embodiment of the present invention, the recombinant cells have a nucleic acid molecule provided in a fourth aspect of the present invention or an expression vector provided in a fifth aspect of the present invention. The vector expresses an antibody or antigen-binding fragment provided in a first aspect of the present invention, or a chimeric antigen receptor provided in a second aspect of the present invention, which is encoded by the nucleic acid molecule. Recombinant cells according to embodiments of the present invention can be used for in vitro expression and large-scale acquisition of the aforementioned antibody or antigen-binding fragment that specifically recognizes CLDN18.2.
[0051] According to one embodiment of the present invention, the aforementioned recombinant cells may further include at least one of the following additional technical features:
[0052] According to one embodiment of the present invention, the recombinant cells are eukaryotic cells, and optionally, the recombinant cells are mammalian cells. Recombinant cells according to embodiments of the present invention are obtained by introducing the aforementioned expression vector into host cells, and the vector can be introduced into host cells by means of electrotransduction, liposomes, injection, etc.
[0053] In a seventh aspect of the present invention, the present invention provides a pharmaceutical composition. According to one embodiment of the present invention, the pharmaceutical composition comprises an antibody or antigen-binding fragment thereof provided in the first aspect of the present invention, a chimeric antigen receptor provided in the second aspect of the present invention, immune cells provided in the third aspect of the present invention, a nucleic acid molecule provided in the fourth aspect of the present invention, an expression vector provided in the fifth aspect of the present invention, or recombinant cells provided in the sixth aspect of the present invention. The antibody contained in or expressed in the pharmaceutical composition according to the embodiment of the present invention can specifically target and bind to CLDN18.2, exhibiting strong specificity and good targeting effect, thereby realizing the biological effects of other drugs in the pharmaceutical composition, such as inhibition of the activity of the CLDN18.2 molecule and killing of cells expressing the CLDN18.2 molecule. Furthermore, the pharmaceutical compositions according to embodiments of the present invention, by relying on antibodies that can specifically target CLDN18.2 as proposed in the first embodiment of the present invention in combination with a diagnostic reagent, play a diagnostic role, and subsequently, by being combined with diagnostic radionuclides, nanomaterials, etc., play a role in diagnosing abnormal expression of the CLDN18.2 portion in organisms, enabling visual observation of cells, tissues, and organs that abnormally express CLDN18.2 in organisms, thereby helping medical workers or scientific researchers make more accurate judgments about lesions.
[0054] In an eighth aspect of the present invention, the present invention provides the use of the aforementioned antibodies or their antigen-binding fragments, chimeric antigen receptors, immune cells, nucleic acid molecules, expression vectors, recombinant cells, and / or pharmaceutical compositions in the manufacture of pharmaceuticals for treating or preventing CLDN18.2-related diseases. According to the application of embodiments of the present invention, pharmaceutical compositions can be used to diagnose, treat, or prevent diseases having abnormal expression of CLDN18.2, such as gastric cancer, pancreatic cancer, and lung cancer.
[0055] According to embodiments of the present invention, the above-described use may further include at least one of the following additional technical features.
[0056] According to one embodiment of the present invention, CLDN18.2-related diseases include tumors.
[0057] According to one embodiment of the present invention, the tumor includes a solid tumor expressing claudin 18.2. Optionally, the solid tumor includes gastric cancer, pancreatic cancer, esophageal cancer, and lung cancer.
[0058] In an eighth aspect of the present invention, the present invention provides a method for diagnosing, treating, or preventing CLDN18.2-related disease in a subject, comprising the step of administering to the subject a therapeutically effective amount of the aforementioned antibody or its antigen-binding fragment, chimeric antigen receptor, immune cells, nucleic acid molecules, expression vectors, recombinant cells, and / or pharmaceutical compositions.
[0059] According to one embodiment of the present invention, CLDN18.2-related diseases include tumors.
[0060] According to one embodiment of the present invention, the tumor includes a solid tumor expressing CLDN18.2. Optionally, the solid tumor includes gastric cancer, pancreatic cancer, esophageal cancer, and lung cancer.
[0061] In an eighth aspect of the present invention, the present invention provides the aforementioned antibodies or antigen-binding fragments thereof, chimeric antigen receptors, immune cells, nucleic acid molecules, expression vectors, recombinant cells, and / or pharmaceutical compositions for use in diagnosing, treating, or preventing CLDN18.2-related diseases in subjects.
[0062] According to one embodiment of the present invention, CLDN18.2-related diseases include tumors.
[0063] According to one embodiment of the present invention, the tumor includes a solid tumor expressing claudin 18.2. Optionally, the solid tumor includes gastric cancer, pancreatic cancer, esophageal cancer, and lung cancer.
[0064] In a ninth aspect of the present invention, the present invention provides a kit for detecting CLDN18.2. According to one embodiment of the present invention, the kit comprises the antibody provided in the first aspect of the present invention. The aforementioned CLDN18.2 antibody can specifically target and bind to CLDN18.2. Kits according to embodiments of the present invention can achieve specific detection of CLDN18.2. For example, if the antibody is bound to a fluorophore, localization or real-time detection of CLDN18.2 can be achieved using a fluorescence detector; if it is bound to biotin and other markers, qualitative or quantitative detection of CLDN18.2 can be achieved by a chromogenic reagent; or the antibody can be combined with an anti-antibody to achieve a sandwich or double sandwich method, and then stepwise amplification of the signal can be achieved to detect CLDN18.2.
[0065] In a tenth aspect of the present invention, the present invention provides the use of the aforementioned antibodies, nucleic acid molecules, expression vectors, or recombinant cells in the manufacture of a kit for detecting CLDN18.2 or diagnosing CLDN18.2-related diseases. According to embodiments of the present invention, the kit can directly detect the expression level of CLDN18.2, such as high expression, low expression, and no expression, thereby enabling the diagnosis of a disease. This can also be combined with other diagnostic reagents, such as in combination with a diagnostic nuclide, to obtain the state of organisms, tissues, and cells, and to visualize the number of cells expressing CLDN18.2 in the body, the size and location of tissues, etc.
[0066] In a tenth aspect of the present invention, the present invention provides a method for detecting CLDN18.2 in a subject or diagnosing a CLDN18.2-related disease using a kit comprising the aforementioned antibody, the aforementioned nucleic acid molecule, the aforementioned expression vector, or the aforementioned recombinant cells.
[0067] In a tenth aspect of the present invention, the present invention provides the aforementioned antibody, the aforementioned nucleic acid molecule, the aforementioned expression vector, or the aforementioned recombinant cell for use in the preparation of a kit for detecting CLDN18.2 or diagnosing CLDN18.2-related disease.
[0068] In an eleventh aspect of the present invention, the present invention provides the use of the aforementioned antibody or its antigen-binding fragment in screening for antibodies capable of recognizing epitopes other than peptide A in CLDN18.2. According to embodiments of the present invention, the antibody and the epitope of peptide A of the antigen tightly combine to form a complex. In this case, the antibody of the present invention blocks the epitope of peptide A of the antigen, and this can be used for antibody screening. The screened antibody can bind to epitopes other than peptide A of the antigen. Furthermore, antibodies that bind to the epitope of peptide A can also be screened, and the screened antibody that binds to the epitope of peptide A has better antigen-binding ability than the antibody of the present invention.
[0069] In an eleventh aspect of the present invention, the present invention provides a method for screening antibodies, comprising using the aforementioned antibody or its antigen-binding fragment, wherein the antibody recognizes an epitope other than peptide A in CLDN18.2.
[0070] In an eleventh aspect of the present invention, the present invention provides an antibody or an antigen-binding fragment thereof for use in antibody screening, wherein the antibody recognizes an epitope other than peptide A in CLDN18.2.
[0071] Additional aspects and advantages of the present invention are partially given in the following description, some of which will be evident from the following description or understood through the practice of the invention.
[0072] The above and / or additional aspects and advantages of the present invention will be evident and readily apparent from the description of the embodiments in conjunction with the following drawings. [Brief explanation of the drawing]
[0073] [Figure 1] This figure shows a mouse serum test after immunization using one embodiment of the present invention. [Figure 2] This figure shows the detection of specificity of m1B6 / m1E7 hybridoma supernatant using one embodiment of the present invention. [Figure 3] This figure shows the affinity detection of an m1B6 / m1E7 monoclonal antibody using one embodiment of the present invention. [Figure 4] This figure shows the nonspecific detection of m1B6 / m1E7 monoclonal antibody using one embodiment of the present invention. [Figure 5] This figure shows the affinity detection of anti-claudin 18.2 scFv-Fc fusion protein using one embodiment of the present invention. [Figure 6] This figure shows epitope identification of an anti-claudin 18.2 antibody according to one embodiment of the present invention. [Figure 7] This figure shows the detection of various anti-claudin 18.2 CAR-T antibodies using one embodiment of the present invention. [Figure 8] This figure shows the positivr rates of various anti-claudin 18.2 CAR-T receptors according to one embodiment of the present invention. [Figure 9] This figure shows the evaluation of anti-claudin 18.2 CAR-T in the NCI-H460 mouse model according to one embodiment of the present invention. [Figure 10] This figure shows the evaluation of anti-claudin 18.2 CAR-T in a Calu-6 mouse model according to one embodiment of the present invention. [Figure 11] This figure shows the detection of ADCC activity of an anti-claudin 18.2 antibody according to one embodiment of the present invention. [Figure 12] This figure shows the detection of CDC activity of an anti-claudin 18.2 antibody according to one embodiment of the present invention. [Figure 13]This figure shows the pharmacodynamic validation of an anti-claudin 18.2 antibody in a BXPC3 tumor model according to one embodiment of the present invention. [Figure 14] This figure shows the detection of body weight changes in a BXPC3 tumor model using an anti-claudin 18.2 antibody according to one embodiment of the present invention. [Modes for carrying out the invention]
[0074] example Embodiments of the present invention are described in detail below. Examples of embodiments are shown in the accompanying drawings, and the same or similar reference numerals indicate the same or similar elements or elements having the same or similar function. The embodiments described below with reference to the accompanying drawings are illustrative and are intended to illustrate the present invention and should not be construed as limiting the present invention.
[0075] Furthermore, the terms “first” and “second” are used for descriptive purposes only and should not be understood as indicating or implying relative importance, or implicitly indicating the number of technical features described. Accordingly, features defined using “first” and “second” may explicitly or implicitly include at least one of the features. In the description of this invention, “plural” means at least two, such as 2, 3, etc., unless specifically defined otherwise.
[0076] In this specification, ADCC refers to antibody-dependent cytotoxicity. When an IgG antibody specifically binds to antigenic determinants on the surface of target cells through its Fab segment, its Fc segment binds to effector cells (NK cells, monocyte-macrophages, neutrophils) such as killer cells possessing FcγR, thereby initiating the toxic activity of the effector cells and directly killing the target cells.
[0077] In this specification, CDC refers to complement-dependent cytotoxicity, meaning that cytotoxicity is related to complement. Specific antibodies bind to the corresponding antigen on the cell membrane surface, forming a complex that activates the classical complement pathway, and the resulting membrane-infiltrating complex exerts a lytic effect on target cells.
[0078] antibody As used herein, the term "antibody" refers to an immunoglobulin molecule capable of binding to a specific antigen. It consists of two light chains with a lower molecular weight and two heavy chains with a higher molecular weight. The heavy (H) and light (L) chains are linked by disulfide bonds to form a tetrapeptide chain molecule. Of these, the amino acid sequence at the amino terminus (N-terminus) of the peptide chain is highly variable and is called the variable region (V region). The carboxyl terminus (C-terminus) is less variable and relatively stable, and is called the constant region (C region). The V regions of the L and H chains are called VL and VH, respectively.
[0079] Some regions within the variable region exhibit a greater degree of variation in amino acid composition and arrangement. These are called hypervariable regions (HVRs). Because hypervariable regions are where antigens and antibodies bind, they are also called complementarity-determining regions (CDRs). There are three CDRs in both the heavy and light chain variable regions.
[0080] In this invention, CLDN18.2 gene knockout C57 mice were immunized using a pCDNA3.4 plasmid containing the full-length h-claudin 18.2 gene, and two anti-CLDN18.2 mouse antibodies with different affinity and binding epitopes were screened via hybridoma fusion technology. The antibody fragments can specifically bind to the CLDN18.2 antigen, which can be used to target the treatment of diseases that abnormally express CLDN18.2, such as tumors.
[0081] In some embodiments, the present invention provides an antibody or antigen-binding fragment capable of specifically recognizing CLDN18.2, comprising at least one CDR sequence selected from the CDR sequences of the light chain variable region shown in SEQ ID NOs: 1-3 and SEQ ID NOs: 7-9, the CDR sequences of the heavy chain variable region shown in SEQ ID NOs: 4-6 and SEQ ID NOs: 10-12, or an amino acid sequence having at least 95% identity thereto. In other embodiments, the antibody or antigen-binding fragment provided by the present invention has conserved amino acid substitutions compared to the heavy and light chains. "Antigen-binding fragment" means an antibody fragment that retains the ability to specifically bind to an antigen (ROR2). Examples of antigen-binding fragments include, but are not limited to, Fv fragments, disulfide bond-stabilized Fv fragments (dsFv), Fab fragments, (Fab)2, scFv-Fc fusion proteins, scFv-Fv fusion proteins, Fv-Fc fusion proteins, and at least one of a polyspecific antibody, a single-domain antibody, a VHH nanobody, a domain antibody, a bivalent domain antibody, or a minimum recognition unit formed from an antigen-binding fragment. "Conservative amino acid substitution" refers to the substitution of an amino acid with a residue that is biologically, chemically, or structurally similar to another amino acid. Biological similarity means that the substitution does not destroy the biological activity of the CLDN18.2 antibody or CLDN18.2 antigen. Structural similarity means that the side chains of amino acids, such as alanine, glycine, or serine, have similar lengths or similar sizes. Chemical similarity means that the amino acids have the same charge, or that both are hydrophilic or hydrophobic. For example, hydrophobic residues such as isoleucine, valine, leucine, or methionine can be substituted for each other. Alternatively, polar amino acids can be used. For example, lysine can be substituted with arginine, aspartic acid with glutamic acid, asparagine with glutamine, or threonine with serine.
[0082] In some embodiments, the present invention provides an antibody or antigen-binding fragment having a heavy chain variable region having the amino acid sequence shown in either SEQ ID NO: 17 or SEQ ID NO: 18, and a light chain variable region having the amino acid sequence shown in either SEQ ID NO: 15 or SEQ ID NO: 16. The inventors can obtain the CDR regions of the anti-heavy chain variable region sequence (shown in SEQ ID NOs: 4-6, SEQ ID NOs: 10-12) and the light chain variable region sequence (shown in SEQ ID NOs: 1-3, SEQ ID NOs: 7-9) through an antibody sequence alignment database (NCBI, IMGT) or related software. In other embodiments, the heavy chain variable region sequence of the antibody or antigen-binding fragment has conserved amino acid substitutions compared to the amino acid sequences shown in SEQ ID NOs: 17 and SEQ ID NO: 18. In some embodiments, the light chain variable region sequence of the antibody or antigen-binding fragment has conserved amino acid substitutions compared to the amino acid sequence shown in either SEQ ID NOs: 15 or SEQ ID NO: 16. Of course, these conserved amino acid substitutions do not alter the biological function of the antibody or antigen-binding fragment. In some specific methods, these conservative amino acid substitutions may occur in amino acids other than those in the CDR region within the heavy chain variable region and the light chain variable region.
[0083] In this invention, the terms "m1B6" and "m1E7" can be understood as mouse antibodies containing heavy and light chains, and the terms "1B6" and "1E7" can be understood as single-chain antibodies formed by a VH-linker-VL. The terms "chimeric antibody 1B6" and "chimeric antibody 1E7" can be understood as chimeric antibodies that retain the variable region of mouse antibodies m1B6 and m1E7 and replace the constant region with human IgG1.
[0084] In some preferred embodiments, the present invention provides an anti-CLDN18.2 antibody having a heavy chain having the amino acid sequence shown in any one of SEQ ID NOs: 21-22, SEQ ID NO: 31, and SEQ ID NO: 33, and a light chain having the amino acid sequence shown in any one of SEQ ID NOs: 19-20, SEQ ID NO: 32, and SEQ ID NO: 34.
[0085] In some preferred embodiments, the present invention provides anti-CLDN18.2 single-chain antibodies having the amino acid sequences shown in SEQ ID NOs. 23-24. The single-chain antibodies of the embodiments of the present invention have a VL-linker-VH structure from the N-terminus to the C-terminus. VL represents the light chain variable region, VH represents the heavy chain variable region, and the linker represents the connecting chain linking VL and VH.
[0086] In some embodiments, the anti-CLDN18.2 antibody of this application has high ADCC and CDC activity with low EC50 and IC50 values, which can effectively act on target cells.
[0087] In some embodiments, the anti-CLDN18.2 antibody of this application can effectively inhibit tumor growth in a mouse model without affecting other physical indicators of the mouse, such as body weight. The antibody of this application has good antitumor effects and fewer side effects.
[0088] Immune cells, chimeric antigen receptors The term "chimeric antigen receptor (CAR)" refers to a molecule that combines antibody-based specificity against a desired antigen (e.g., a tumor antigen) with an intracellular domain that activates T cell receptors to produce a chimeric protein that exhibits specific anti-tumor cell immune activity.
[0089] Immune cells or chimeric antigen receptors can be prepared using antibodies or antigen-binding fragments thereof that can specifically recognize CLDN18.2.
[0090] To achieve this objective, the present invention also provides a chimeric antigen receptor comprising an extracellular region, wherein the extracellular region comprises a heavy chain variable region and a light chain variable region of a single-chain antibody. Here, the light chain variable region and the heavy chain variable region are selected from the aforementioned antibody or its antigen-binding fragment that can specifically recognize CLDN18.2. In addition to the heavy chain variable region and the light chain variable region of the single-chain antibody, the extracellular region also comprises a hinge region that supports the single-chain variable fragment.
[0091] In some embodiments, the variable weight and light chains in the chimeric antigen receptor are linked together by a short peptide. In addition to the extracellular domain, the chimeric antigen receptor further comprises a transmembrane domain and an intracellular domain. These domains can initiate an intracellular signaling cascade for antigen recognition.
[0092] In some embodiments, the intracellular region is selected from the CD3ζ, FcεRIγ, CD27, CD28, CD137, CD134, MyD88, CD40 intracellular signaling region sequences, or a combination thereof, or the transmembrane region includes the CD8 or CD28 transmembrane region. In some embodiments, the chimeric antigen receptor includes an antibody, a transmembrane region, and an intracellular region linked in the following order: the antibody of the present invention, CD8, and CD3ζ; the antibody of the present invention, CD8, CD137, and CD3ζ; or the antibody of the present invention, the transmembrane region of the CD28 molecule, the intracellular signaling region of the CD28 molecule, and CD3ζ; or the antibody of the present invention, the transmembrane region of the CD28 molecule, the intracellular signaling region of the CD28 molecule, CD137, and CD3ζ.
[0093] In some embodiments, the transmembrane region includes an immunocostimulatory factor transmembrane region. In some embodiments, the immunocostimulatory factor transmembrane region may further be a CD8 transmembrane region or an ICOS transmembrane region.
[0094] In some embodiments, the intracellular region includes the intracellular segment of the immunostimulator and the CD3ζ chain.
[0095] In some embodiments, the intracellular segment of the immunostimulator further comprises ICOS, 4-IBB, or OX-40 fused with an intracellular signaling domain derived from a CD3ζ sequence.
[0096] In some embodiments, the chimeric antigen receptor further comprises two costimulatory molecules fused using the CD3ζ internal domain on a single-chain single vector (such as a retroviral vector) or a double-chain single vector (such as a retroviral vector). A cleaved double-chain single vector expresses two strands, one of which contains an scFv fused with the costimulatory molecule and the CD3ζ internal domain.
[0097] In some embodiments, the chimeric antigen receptor further includes a cytokine receptor and a chemotactic receptor.
[0098] Based on the fact that the aforementioned chimeric antigen receptors can prepare immune cells, immune cells can express the aforementioned chimeric antigen receptors.
[0099] In some embodiments, the immune cells include at least one of T lymphocytes, DC cells, NK cells, and NKT lymphocytes. In some embodiments, the immune cells can specifically kill cancer cells having CLDN18.2 on their surface and exhibit good killing effects in vivo and in vitro.
[0100] T cells that express CAR are called CAR T cells or CAR-modified T cells.
[0101] The CARs of embodiments of the present invention (including their functional portions and functional variants) can be obtained by methods known in the art. The CARs can be prepared by any suitable method for preparing polypeptides or proteins. Suitable methods for the novel synthesis of polypeptides and proteins are described in reference to Chan et al., Fmoc Solid Phase Peptide Synthesis, Oxford University Press, Oxford, UK, 2000; Peptide and Protein Drug Analysis, edited by Reid, R., Marcel Dekker Inc., 2000; Epitope Mapping, edited by Westwood et al., Oxford University Press, Oxford, UK, 2001; and U.S. Patent No. 5,449,752. Furthermore, polypeptides and proteins can be recombinantly produced using the nucleic acids described herein and standard recombination methods. For example, see Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd edition, Cold Spring Harbor Press, Cold Spring Harbor, New York, 2001, and Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates and John Wiley & Sons, New York, 1994. Furthermore, some CARs of the present invention (including functional parts and functional variants) can be isolated and / or purified from sources such as plants, bacteria, insects, mammals, e.g., rats, humans. Methods for isolation and purification are well known in the art. Alternatively, the CARs described herein (including their functional parts and functional variants) can be commercially synthesized by companies such as Synpep (Dublin, California), Peptide Technologies Corp. (Gaithersburg, Maryland), and Multiple Peptide Systems (San Diego, California). From this perspective, the CARs of the present invention can be synthesized, recombinant, isolated, and / or purified.
[0102] In some embodiments, the immune cells also have an exogenous cytokine coding sequence, or they express another chimeric antigen receptor that does not contain CD3ζ but contains the intracellular signaling domain of CD28, the intracellular signaling domain of CD137, or a combination of both, or they also express a chemokine receptor, preferably the chemokine receptor containing a CCR, or they also express an siRNA that can reduce PD-1 expression or a protein that blocks PD-L1, or endogenous PD-1 in the cell is knocked out by gene editing technology, or they also express a safety switch.
[0103] In another aspect of the present invention, the present invention also provides a multifunctional immune conjugate comprising the antibody of the present invention and a functional molecule linked thereto, wherein the functional molecule is selected from molecules that target tumor surface markers, molecules that inhibit tumors, molecules that target immune cell surface markers, or detectable markers. In some embodiments, the molecule that targets immune cell surface markers is an antibody that binds to T cell surface markers, thereby forming a bifunctional antibody in which the T cell participation and the antibody of the present invention are involved.
[0104] As used herein, the term "costimulatory molecule" refers to a homologous binding partner on immune cells such as T cells that specifically binds to a costimulatory ligand and thereby mediates a costimulatory response, such as proliferation, but is not limited to this. Costimulatory molecules are cell surface molecules other than antigen receptors or their ligands that promote an effective immune response. Examples of costimulatory molecules, but are not limited to these, include MHC I molecules, BTLA and Toll ligand receptors, as well as OX40, CD27, CD28, CDS, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278), and 4-1BB (CD137). Examples of co-stimulatory molecules, though not limited to these, include CDS, ICAM-1, GITR, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD160, CD19, CD4, CD8α, CD8β, IL2Rβ, IL2Rγ, IL7Rα, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, and ITGB. 2. CD18, LFA-1, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp, and CD19 are examples.
[0105] The term "scFv" refers to a fusion protein comprising at least one variable region antibody fragment containing a light chain and at least one variable region antibody fragment containing a heavy chain, wherein the light and heavy chain variable regions are contiguous (e.g., via a synthetic linker such as a short, flexible polypeptide linker), and can be expressed as a single-chain polypeptide. The scFv retains the specificity of the intact antibody from which it is derived. Unless otherwise specified, the scFv as used herein may have the VL and VH variable regions in any order (e.g., relative to the N-terminus and C-terminus of the polypeptide), and the scFv may contain a VL-linker-VH or a VH-linker-VL.
[0106] As used herein, the term “epitope” and other grammatical forms may refer to a portion of an antigen that can be recognized by an antibody, B cell, T cell, or engineered cell. For example, an epitope may be a tumor epitope or pathogen epitope recognized by a TCR, or it may recognize multiple epitopes in a single antigen. Epitopes can also be mutated.
[0107] nucleic acid molecules, expression vectors, recombinant cells In the process of preparing or obtaining these antibodies or chimeric antigen receptors, nucleic acid molecules expressing these antibodies or chimeric antigen receptors can be linked to various vectors and expressed in various cells to obtain the corresponding antibodies or chimeric antigen receptors.
[0108] To achieve this objective, the present invention also provides isolated nucleic acid molecules encoding the aforementioned antibodies or their antigen-binding fragments or chimeric antigen receptors.
[0109] In some preferred embodiments, nucleic acid molecules are species-optimized to facilitate their expression in mammalian cells.
[0110] The present invention also provides expression vectors containing the isolated nucleic acid molecules described above. When isolated polynucleotides are linked to a vector, the polynucleotides can be linked directly or indirectly to regulatory elements on the vector, insofar as the regulatory elements can control the translation and expression of the polynucleotides. Of course, these regulatory elements can come directly from the carrier itself or be exogenous, i.e., not from the carrier itself. Of course, polynucleotides can be operably linked to regulatory elements. Here, "operably linked" means a link between the exogenous gene and the vector such that regulatory elements in the vector, such as transcriptional regulatory sequences and translational regulatory sequences, can perform their expected function of regulating the transcription and translation of the exogenous gene. Of course, polynucleotides used to encode the heavy and light chains of antibodies can be inserted independently into various vectors, although it is common to insert them into the same vector. Commonly used vectors may be plasmids, bacteriophages, etc.
[0111] The present invention also provides recombinant cells containing expression vectors. Recombinant cells can be constructed by introducing the expression vector into mammalian cells, and then these recombinant cells can be used to express antibodies or antigen-binding fragments provided by the present invention. The corresponding antibodies can be obtained by culturing the recombinant cells. These usable mammalian cells may be, for example, CHO cells.
[0112] Pharmaceutical compositions, kits, and their pharmaceutical use, as well as their use in the preparation of kits. The present invention also provides a pharmaceutical composition comprising the above-mentioned antibody or its antigen-binding fragment and a pharmaceutically acceptable carrier, and may also include the above-mentioned chimeric antigen receptor, immune cells, nucleic acid molecules, expression vectors, and recombinant cells.
[0113] The CLDN18.2 antibody provided herein can be incorporated into a pharmaceutical composition suitable for administration to a target. Generally, these pharmaceutical compositions contain the CLDN18.2 antibody provided herein.
[0114] In some embodiments, these pharmaceutical compositions further include a pharmaceutically acceptable carrier suitable for a specific target dosage form, comprising any solvent, solid excipient, diluent, binder, disintegrant, or other liquid excipient, dispersant, flavoring or suspending agent, surfactant, isotonic agent, thickener, emulsifier, preservative, solid binder, flow enhancer, or lubricant. It is intended that the use of any conventional excipient is incompatible with the compounds disclosed herein, for example, by producing any undesirable biological effect or by otherwise interacting in a detrimental manner with any other component of the pharmaceutically acceptable composition.
[0115] For example, the antibodies of the present invention can be incorporated into pharmaceutical compositions suitable for parenteral administration (e.g., intravenous, subcutaneous, intraperitoneal, intramuscular). These pharmaceutical compositions can be prepared in various forms, including, but are not limited to, liquid solutions (e.g., injectable solutions and infusion solutions), dispersions or suspensions, tablets, pills, powders, liposomes, and suppositories, as well as liquid, semi-solid, and solid dosage forms. Typical pharmaceutical compositions are in the form of injectable or infusion solutions. Antibodies can be administered by intravenous infusion or injection, or by intramuscular or subcutaneous injection.
[0116] Of course, the CLDN18.2 antibody as used herein can also be part of a kit or other diagnostic reagent as needed. According to one embodiment of the present invention, the present invention also provides a kit comprising the CLDN18.2 antibody described above. The kit provided by the present invention can be used, for example, for immunoblotting, immunoprecipitation, etc., which involves the use of the specific binding properties of the CLDN18.2 antigen and the antibody to be detected. These kits may contain any one or more of the following: an antagonist, CLDN18.2 antibody, or drug reference substance, protein purification column, immunoglobulin affinity purification buffer, cell assay diluent, instructions, or literature. The CLDN18.2 antibody can be used in various types of diagnostic tests, for example, to detect the presence of various diseases or drugs, toxins, or other proteins in vitro or in vivo. For example, serum or blood of a subject can be tested for the relevant disease, such as cancer or tumors, which can be any uncontrolled cell growth.
[0117] In some embodiments, the CLDN18.2 antibody can be used in combination with any detection reagent or therapeutic agent, such as a diagnostic nuclide or nanomaterial, to detect a target site through the radioactivity of the nuclide in order to obtain information about the target site. It can also be used in combination with a therapeutic nuclide to specifically kill target cells, tissues, etc., using the radioactivity of the nuclide.
[0118] When using the CLDN18.2 antibody provided by the present invention to diagnose, treat, or prevent the aforementioned diseases, the CLDN18.2 antibody provided by the present invention can be provided to a target. To achieve this objective, the present invention provides a method for treating the aforementioned diseases, comprising the step of administering the antibody or its antigen-binding fragment provided by the present invention to a target in need.
[0119] The terms “treatment” and “prevention” as used herein, and words derived therefrom, do not necessarily imply 100% or complete treatment or prevention. Rather, there are varying degrees of treatment or prevention, and those skilled in the art will understand that treatment or prevention may have potential benefits or therapeutic effects. From this perspective, the methods of the present invention can provide treatment or prevention of any amount or level of cancer in mammals. Furthermore, the treatment or prevention provided by the methods of the present invention may include treatment or prevention of the disease being treated or prevented, such as treatment or prevention of one or more diseases or symptoms of cancer. Furthermore, for the purposes of this document, “prevention” may include delaying the onset of the disease or its symptoms or in a patient.
[0120] The present invention will be described below with reference to specific embodiments. Note that these embodiments are for illustrative purposes only and do not limit the invention in any way. Where specific techniques or conditions are not shown in the examples, the techniques or conditions described in the art literature or product descriptions shall be followed. Unless otherwise specified by the manufacturer, the reagents or equipment used are all commercially available, commonly used products. [Examples]
[0121] Monoclonal screening and activity identification of anti-claudin 18.2 1.1 Screening of anti-claudin 18.2 monoclonal antibodies: Mouse immunology and hybridoma screening: C57 mice with claudin 18.2 gene knockout were immunized with the pCDNA3.4 plasmid containing the full-length h-claudin 18.2 gene. Each mouse was immunized by intramuscular injection with 60 μg of plasmid, and a total of 10 mice were immunized. The immunization interval was 2 weeks. Blood was collected on day 7 after three plasmid immunizations, and serum was diluted 100-fold. The immune response of the mice was detected using 293T cells with high expression of h-claudin 18.2. Mice with an obvious immune response were selected for tail vein or intraperitoneal impulse immunization using 293T cells with high expression of h-claudin 18.2 (Figure 1), with each mouse receiving an inoculation of 1E+07 cells. Three to four days later, mouse spleens were harvested, pulverized using a 70 μm mesh, then fused with SP2 / 0 cells using PEG, seeded, and CHO cells with high expression of h-claudin 18.2 were used for hybridoma screening.
[0122] 1.2 Preparation of cell lines containing high expression of h-claudin 18.2 and h-claudin 18.1-CHO: Cell lines expressing high levels of h-claudin 18.2-CHO and h-claudin 18.1-CHO were each collected at approximately 5E+06 cells, with cell viability exceeding 95%. Cells were collected by centrifugation at 500g for 3 minutes, washed with an equal volume of pre-cooled PBS containing 1% BSA, centrifuged three times, and then resuspended in pre-cooled PBS containing 1% BSA at a density of 1E+07 cells / mL. Each cell type was divided into four flow detection tubes at a volume of 100 μL / tube.
[0123] 1.3 Treatment of the supernatant of m1B6 / m1E7 anti-claudin 18.2 monoclonal hybridoma: Two aliquot-divided cells were numbered as h-claudin 18.2-CHO-NC, h-claudin 18.2-CHO-mouse secondary antibody, h-claudin 18.2-CHO-m1B6, and h-claudin 18.2-CHO-m1E7. 100 μL of pre-cooled PBS containing 1% BSA was added to the NC-numbered samples and the mouse secondary antibody and thoroughly mixed. 100 μL of the corresponding m1B6 / m1E7 monoclonal hybridoma cell line supernatant was added to the flow tube corresponding to the m1B6 / m1E7 label and thoroughly mixed. After reacting all samples at 4°C for 30 minutes, cells were collected by centrifugation at 500 g for 3 minutes, washed with an equal volume of pre-cooled PBS containing 1% BSA, centrifuged three times, and then collected for later use.
[0124] Preparation of mouse secondary antibody diluents: PE-labeled GAM-IgG-PE-labeled (ab97024) was diluted in a 1:500 ratio to a total of 2 mL using pre-cooled PBS containing 1% BSA. The mixture was thoroughly mixed and stored at 4°C for later use. The diluted mouse secondary antibody diluents h-claudin 18.2-CHO-mouse secondary antibody, h-claudin 18.2-CHO-m1B6, and h-claudin 18.2-CHO-m1E7 were collected in 200 μL / tube quantities. Cells treated with h-claudin 18.1-CHO-mouse secondary antibody, h-claudin 18.1-CHO-m1B6, and h-claudin 18.1-CHO-m1E7 were resuspended. After resuspending cells in 200 μL of pre-cooled PBS containing 1% BSA in 1 / h claudin 18.2-CHO-NC and 1 / h claudin 18.1-CHO-NC, all treated samples were allowed to react statically at 4°C for 30 minutes. Subsequently, cells were collected by centrifugation at 500 g every 3 minutes, washed with an equal volume of pre-cooled PBS containing 1% BSA, centrifuged three times, and then collected for later use.
[0125] 1.4 Flow detection: Flow potentials were confirmed using h-claudin 18.2-CHO-NC and h-claudin 18.1-CHO-NC samples. Negative detection values were confirmed using h-claudin 18.2-CHO-mouse secondary antibody and h-claudin 18.1-CHO-mouse secondary antibody samples. Established flow templates for detecting h-claudin 18.2-CHO-m1B6 and h-claudin 18.2-CHO-m1E7. Flow cytometry results for h-claudin 18.1-CHO-m1B6 and h-claudin 18.1-CHO-m1E7 samples showed a very good specific response for m1B6 / m1E7, and the results are shown in Figure 2. [Examples]
[0126] Affinity and specificity detection of anti-claudin 18.2m1B6 / m1E7 monoclonal antibody Production and purification of ascites with anti-claudin 18.2m1B6 / m1E7 Ten female BALB / c mice were taken, and each was injected intraperitoneally with 0.5 mL of paraffin oil. After 10 days, the mice were ready for later use. The ten mice were divided into two cages of five mice each. Each mouse was injected intraperitoneally with 1E+06 cells of the pre-treated 1B6 / 1E7 monoclonal cell line. After 10–12 days, ascites fluid produced by the mice was collected, and each cell line was collected from approximately 10 mL of ascites fluid for later use.
[0127] The collected ascites fluid was centrifuged at 12,000 g for 10 minutes to collect the supernatant, and then 50% saturated ammonium sulfate was added. The mixture was thoroughly mixed and refined at 4°C for 30 minutes, then centrifuged at 10,000 g for 10 minutes to collect the precipitate. The precipitate was resuspended in an equal volume of PBS and filtered through a 0.45 μm filter membrane to prepare it for use.
[0128] Using PBS, a protein A affinity chromatography column (5 mL pre-packed column) was equilibrated at a flow rate of 4 mL / min. After equilibrating five column volumes, pre-treated m1B6 / m1E7 was loaded and purified at a rate of 4 mL / min. After loading the sample, rinsing was continued with PBS until the detection baseline stabilized, and then 0.1 M pH 3.5 acetic acid was used for elution. Elution peaks were collected, and the pH of the eluate was adjusted to pH 7.4 using 1 M Tris buffer. After purification, the protein A chromatography column was washed 5 CV with 0.1 M NaOH buffer, washed with PBS until the pH was neutral, and then washed with purified water until the baseline of each test stabilized. The protein A column was stored in 20% ethanol. The m1B6 / m1E7 eluted samples were transferred to a 25 kD dialysis bag and dialyzed in PBS for later use.
[0129] CHOs overexpressing claudin 18.1 cells and claudin 18.2 cells were prepared, centrifuged at 300 g for 5 minutes, and then resuspended in PBS. This step was repeated twice. Finally, the concentration was adjusted to 3E+06 cells / mL using PBS. The two antibodies were diluted from 2.5 μg / mL to 0.005 μg / mL using a 2x gradient with 10 gradients. 100 μL each of the claudin 18.1 cell-overexpressing CHO and the claudin 18.2 cell-overexpressing CHO were placed in two rows of clear 96 round-bottom wells, and the antibodies were then added to the cells in order and mixed uniformly in a 1:1 ratio. Each was designated as a blank well and a negative well. The mixtures were incubated in a refrigerator at 4°C for 1 hour. After incubation, the mixtures were centrifuged in a high-capacity benchtop centrifuge at 500 g for 3 minutes, and then resuspended in PBS. This step was repeated three times. Diluting PE-labeled goat anti-mouse secondary antibody to a concentration of 1:500, 100 μL was added to each well. Nothing was added to the blank wells. The mixture was incubated in a refrigerator at 4°C for 30 minutes. After incubation, the mixture was centrifuged at 500 g for 3 minutes in a high-capacity tabletop high-speed centrifuge, then resuspended in PBS, and this step was repeated three times. Finally, 180 μL of PBS was added to each well, and a BDverse flow cytometer was used for testing. EC of m1B6 50 It is approximately 0.06 μg / mL, and the EC of m1E7 50 The concentration was approximately 0.1 μg / mL. This concentration did not cross-react with claudin 18.1, and the concentration of 20 μg / mL also did not cross-react with claudin 18.1, indicating good specificity. The results are shown in Figures 3 and 4. [Examples]
[0130] Activity detection of anti-claudin 18.2 scfv-FC fusion protein Sequence determination of 1B6 and 1E7 hybridoma cell lines was commissioned to Beijing Qingke Biotechnology Co., Ltd. An expression vector for the anti-claudin 18.2 scFv-Fc fusion protein was constructed by molecular cloning. The constructed expression vector was transiently transformed into 293F cells to express the anti-claudin 18.2 scFv-FC fusion protein. The supernatant was collected and centrifuged at 12000g for 10 minutes, after which it was ready for later use. Using a protein A chromatography column, a protein A affinity chromatography column (5 mL pre-packed column) was equilibrated with PBS at a flow rate of 4 mL / min. After equilibration of the column volume, the pre-treated m1B6 / m1E7 (Fc fusion protein form) was loaded and purified at a rate of 4 mL / min. After loading the sample, rinsing with PBS was continued until the detection baseline stabilized, and then 0.1 M pH 3.5 acetic acid was used for elution. Elution peaks were collected, and the pH of the eluate was adjusted to pH 7.4 using 1 M Tris buffer. After purification, the protein A chromatography column was washed 5 CV with 0.1 M NaOH buffer, washed with PBS until the pH was neutral, and then washed with purified water until the baseline of each test was stable. The protein A column was stored in 20% ethanol. The 1B6 / 1E7 eluted samples were transferred to a 25 kD dialysis bag and dialyzed in PBS for later use.
[0131] CHOs overexpressing claudin 18.2 cells were prepared, centrifuged at 300 g for 5 minutes, and then resuspended in PBS. This step was repeated twice. Finally, the concentration was adjusted to 3E+06 cells / mL using PBS. Three antibodies, m1B6 / m1E7 / IMAB362-FC, were diluted from 40 μg / mL to 0.04 μg / mL using a 4-fold gradient and 6 gradients. 100 μL each of the CHOs overexpressing claudin 18.1 cells and the CHOs overexpressing claudin 18.2 cells were placed in two rows of clear 96 round-bottom wells. The antibodies were then added to the cells in order and mixed uniformly in a 1:1 ratio. Each was designated as a blank well and a negative well. The mixtures were incubated in a refrigerator at 4°C for 1 hour. After incubation, the mixtures were centrifuged in a high-capacity benchtop centrifuge at 500 g for 3 minutes, and then resuspended in PBS. This step was repeated three times. Diluting PE-labeled goat anti-human secondary antibody to a concentration of 1:500, 100 μL was added to each well. Nothing was added to the blank wells. The mixture was incubated in a refrigerator at 4°C for 30 minutes. After incubation, the mixture was centrifuged at 500 g for 3 minutes in a high-capacity tabletop high-speed centrifuge, then resuspended in PBS, and this step was repeated three times. Finally, 180 μL of PBS was added to each well, and a BDverse flow cytometer was used for testing. EC of m1B6-FC 50 The EC of m1E7-FC is approximately 0.5 μg / mL. 50 The EC of IMAB362-FC is approximately 2.6 μg / mL. 50 The concentration was approximately 2.0 μg / mL. m1B6 had a higher affinity, while m1E7 had the same affinity as existing clinical antibodies. The results are shown in Figure 5. [Examples]
[0132] Epitope identification of anti-claudin 18.2 antibody 1B6 / 1E7 Various peptides of h-claudin 18.2 were synthesized according to the following amino acid sequences: 18.2EL1-A:DQWSTQDLYNNPVTAVFNYQGC, 18.2EL1-B:YQGLWRSCVRESSGFTECRG, 18.2EL1-C:CRGYFTLLGLPAmLQAVR, 18.2EL1-D:VRESSGFTECRGYFTLLGLP, 18.2EL1-E:DLYNNPVTAVFNYQGLWRSC, 18.2EL1-F:DQWSTQDLYNNPVTC, 18.2EL1-G:AVFNYQGLWRSC, 18.2EL1-H:CVRESSGFTE, 18.2EL1-I:CRGYFTLLGL. The nine synthesized peptides were dissolved in water:acetonitrile = 3:1 by sonication, and the final concentration after dissolution was 1 mg / mL. For later use, each peptide was divided into 100 μL / 1.5 mL EP tubes. m1B6 was diluted to 2 μg / mL in a total of 1 mL, m1E7 mAb to 4 μg / mL in a total of 1 mL, and IMAB362 to 20 μg / mL in a total of 1 mL. The three diluted anti-claudin 18.2 antibodies were thoroughly mixed with the aliquot-divided peptides in a 1:1 volume ratio. A control group was established, and the diluted m1B6, m1E7, and IMAB362 were thoroughly mixed with PBS in a 1:1 volume ratio. The above mixtures were placed in a refrigerator at 4°C for 30 minutes.
[0133] CHOs overexpressing claudin 18.2 cells were collected, then centrifuged at 300 g for 5 minutes and resuspended in an equal volume of PBS. The centrifugation and resuspension steps were repeated twice. Finally, the concentration was adjusted to 3E+06 cells / mL using PBS. 100 μL of cell suspension (two blank control wells and one negative control well) was added to each well of a clear 96 round-bottom well, centrifuged at 300 g for 5 minutes, the supernatant was removed, and the cell pellet was saved for later use.
[0134] The incubated antibody-peptide mixture was added to the corresponding cell pellet, thoroughly mixed with the cells, and labeled. The mixture was then incubated in a 4°C refrigerator for 30 minutes. After incubation, the mixture was centrifuged at 300g for 5 minutes and resuspended in PBS. This step was repeated three times. PE-labeled goat anti-mouse secondary antibody was diluted to a concentration of 1:500, and 100 μL was added to each well. Nothing was added to the blank wells. The mixture was incubated in a 4°C refrigerator for 30 minutes. After incubation, the mixture was centrifuged at 300g for 5 minutes and resuspended in PBS; this step was repeated three times. Finally, 180 μL of PBS was added to each well, and cell fluorescence intensity was detected using a BD flow cytometer. m1B6 bound to a complex epitope consisting of peptides A and E, with peptide A being its dominant epitope. m1E7 bound only to the epitope where peptide A was located. IMAB362 bound to a complex epitope consisting of peptides A, C, and E, with peptide E being the dominant epitope. The results are shown in Figure 6. [Examples]
[0135] Detection of in vitro tumor-killing activity of anti-claudin 18.2 CAR-T Anti-claudin 18.2 CAR-T cells were constructed (m1B6 / m1E7 / IMAB362). The CAR structure was as described above, containing a signal peptide-anti-claudin 18.2 scfv-CD8 hinge + CD8™-ICOS-4-1BB-CD3ζ. The amino acid sequences of anti-claudin 18.2 scfv were the 1B6 or 1E7 sequences shown in SEQ ID NOs. 23 and 24, respectively. The amino acid sequences of other structures (signal peptide, CD8 hinge, etc.) are shown in SEQ ID NOs. 25-30.
[0136] 293T cells were seeded according to a volume of 6E+06 cells / 10cm in a cell culture dish and cultured overnight at 37°C and 5% CO2 for later use. The seeded cells were observed the following day to see if they had reached a concentration of 95%–99%.
[0137] Lentivirus packaging systems were prepared according to Table 1 (each a 10 cm packaging system, containing m1B6 / m1E7 / IMAB362 / GFP lentiviruses, respectively).
[0138] [Table 1]
[0139] After preparing A / B, the mixture in tube A was transferred to tube B. The resulting mixture was gently and thoroughly mixed, and then allowed to stand in the dark for 10-20 minutes. For later use, 9 mL of DMEM medium containing 10% FBS was added and thoroughly mixed.
[0140] 293 T cells (in a 10 cm cell culture dish) were pre-prepared, and the supernatant was removed. The corresponding A / B mixed product was gently transferred to the corresponding cell culture dish, and the corresponding labels were prepared. After culturing at 37°C and 5% CO2 for 6 hours, the mixture was replaced with fresh T cells containing healthy human T cells isolated by Ficoll lymphocyte isolation solution, and cultured in a 24-well plate at 1E+06 cells / well. Simultaneously, magnetic beads coupled with CD3 / CD28 antibody (Invitrogen) were added to stimulate the T cells. After 48 hours, the corresponding lentivirus was added for infection. IL-2 (300 U / mL) was added during viral infection, and CAR-T cells were expanded until day 6 or 7 to detect CAR gene expression, which was then used in subsequent experiments.
[0141] Effective target ratios of CAR-T and effector cells (H460 / 18.2-H460) were set to 1:3, 1:1, 3:1, and 9:1. Effector cells were collected and centrifuged in a centrifuge tube at 400 g for 5 minutes. The supernatant was discarded. The resulting mixture was washed once with an appropriate amount of PBS, centrifuged, the supernatant was removed, and then 0.5 mL of CTS complete medium was added to resuspend the mixture. The cell density and positivity corresponding to CAR-T were detected. For later use, the cells were adjusted to the appropriate density in CTS complete medium. An appropriate amount of diluted effector cells was added to a 96-well cell detection plate, centrifuged at 400 g for 5 minutes, and the supernatant was removed. 100 μL of CAR-T of various densities was added to the corresponding wells, the cells were gently resuspended and thoroughly mixed, and then 100 μL of CTS was added to each well. The mixture was incubated for 20 hours and then tested as follows.
[0142] After incubation for 20 hours, 20 μL of lysis buffer was added to the Vcc well and TMR well and thoroughly mixed. The mixture was dissolved at 37°C for 30 minutes.
[0143] The mixture was centrifuged at 400g for 5 minutes at room temperature, and 100 μL of the supernatant was transferred to a 96-well plate. Samples were also collected for cytokine release.
[0144] 100 μL of the working solution was added to each well.
[0145] The mixture was incubated in the dark at room temperature for 30 minutes.
[0146] 50 μL of stop solution was added to each well, and the absorbance at 490 nm was measured.
[0147] In comparison, the CAR-T constructed with 1B6 / 1E7 showed a clear killing effect in vitro and a significant dose-response relationship. Compared to the CAR-T constructed with IMAB362, this had a stronger killing effect and a higher CAR positivity rate. The results are shown in Figures 7 and 8.
Example
[0148] Detection of in vivo killing activity of anti-claudin 18.2 CAR-T (claudin 18.2 NCI-H460 cells) Claudin 18.2 NCI-H460 cells and NCI-H460 cells were cultured in RPMI-1640 medium (containing 10% FBS) and placed in a 37 °C, 5% carbon dioxide incubator. After the cells grew to the required number, the cells were collected during the logarithmic growth phase. The original medium was discarded, and the mixture was treated with trypsin for 3 minutes. Then, digestion was stopped using RPMI-1640 medium containing 10% FBS, the cells were collected, and centrifuged at 1000 rpm for 5 minutes. After cell counting, the cell density was adjusted to 5E+07 cells / mL using a mixture of serum-free RPMI-1640 medium and Matrigel (1:1 ratio). Fixed NOD / SCID female mice were captured, and the cell suspension was injected subcutaneously into the right back of the mice at 100 μL / mouse. In the claudin 18.2 NCI-H460 model, when the tumor grew to about 150 mm 3 up to, the animals were administered in groups. In the NCI-H460 model, when the tumor grew to about 250 mm 3 up to, the animals were administered in groups. Each model was divided into a total of 2 groups of 6 animals each in the vehicle group and the anti-claudin 18.2-1B6 CAR-T group. Anti-claudin 18.2-1B6 CAR-T cells were collected, and the cell density was adjusted to 1E+08 cells / mL using PBS solution. The cell suspension was injected into the tumor at 50 μL / mouse. In the vehicle group, PBS solution was injected into the tumor at 50 μL / mouse. The length and width of the tumor were measured once every 2 days or twice a week, and the tumor volume was calculated (tumor volume = tumor length * × tumor width * × tumor width / 2). The tumor growth inhibition rate (TGI) was calculated. When TX > T0, TGI = [1 - TX / CX] * × 100%, and when TX < T0, TGI = [1 - (TX - T0) / T0] *The percentage is 100%. TX and CX represent tumor volume on the measurement day, while T0 and C0 represent tumor volume on the administration day. Statistical analysis was performed using SPSS 16.0.
[0149] In a transplanted tumor model established using claudin 18.2 NCI-H460 cells in NOD / SCID mice, anti-claudin 18.2-1B6 CAR-T significantly inhibited tumor growth after intratumoral administration. At the end of the experiment, the tumor growth inhibition rate reached 134.78%. Statistical analysis of tumor volume between the two groups revealed a significant statistical difference (P<0.01).
[0150] In a transplanted tumor model established using NCI-H460 cells in NOD / SCID mice, anti-claudin 18.2-1B6 CAR-T failed to inhibit tumor growth after intratumoral administration. At the end of the experiment, the tumor growth inhibition rate was 2.17%. Statistical analysis of tumor volume between the two groups revealed no statistically significant differences. The results are shown in Figure 9. [Examples]
[0151] Detection of in vivo killing activity of anti-claudin 18.2 CAR-T cells (claudin 18.2 Calu-6 cells). Claudin 18.2 Calu-6 cells were cultured in RPMI-1640 medium (containing 10% FBS) and placed in a 37°C, 5% carbon dioxide incubator. After the cells had grown to the required number, they were harvested during the logarithmic growth phase. The original medium was discarded, and the mixture was trypsinized for 3 minutes. Digestion was then stopped using RPMI-1640 medium containing 10% FBS, the cells were collected, and centrifuged at 1000 rpm for 5 minutes. After cell counting, the cell density was adjusted to 2.5E+07 cells / mL using a mixture of serum-free RPMI-1640 medium and Matrigel (1:1 ratio). Fixed NCG female mice were captured, and the cell suspension was injected subcutaneously into the right dorsal region of the mouse at a rate of 100 μL / mouse. The tumor was approximately 150 mm. 3When it had grown to [the relevant stage], it was administered to animals in groups. The experiment was divided into a total of three groups of eight animals each in the vehicle group, the T cell group, and the Claudin 18.2 CAR-T (1B6) group. Claudin 18.2 CAR-T (1B6) cells and T cells were collected, and the cell density was adjusted to 1E+08 cells / mL using a PBS solution. The cell suspension was injected into the tail vein at 200 μL / mouse. In the vehicle group, the PBS solution was injected intravenously into the tail vein at 200 μL / mouse. The length and width of the tumor were measured twice a week, and the tumor volume was calculated (tumor volume = tumor length * × tumor width * / 2). The tumor growth inhibition rate (TGI) was calculated. When TX > T0, TGI = [1 - TX / CX] * × 100%, and when TX < T0, TGI = [1 - (TX - T0) / T0] * × 100%. TX and CX were the tumor volumes on the measurement days, and T0 and C0 were the tumor volumes on the administration day. Statistical analysis was performed using SPSS 16.0.
[0152] In the transplanted tumor model established by Claudin 18.2 Calu-6 cells in NCG mice, Claudin 18.2 CAR-T (1B6) could significantly inhibit tumor growth after intratumoral administration. At the end of the experiment, the tumor growth inhibition rate was 106.56%. The Claudin 18.2 CAR-T (1B6) group, the vehicle group, and the T cell group were statistically analyzed, and there was a significant statistical difference P < 0.01. The results were as shown in Figure 10.
Example
[0153] Detection of the ADCC activity of the anti-Claudin 18.2 chimeric antibody In this example, a Jarcut-NFAT-Luc-CD16 luciferase reporter gene cell line was used, in which CD16 receptor and NFAT (activated T cell nuclear factor) reaction elements were stably transfected. When the Fab fragments of the test antibodies (chimeric antibodies 1B6, 1E7) and the control antibody IMAB362 bound to antigens on target cells BXPC-3-claudin 18.2, Capan-1-claudin 18.2, and SK-GT-claudin 18.2, the Fc segment of the antibodies bound to the surface (FcγRIIIA) of effector cells, Jarcut-NFAT-luciferase-CD16 cells, induced activation of the NFAT-related signaling pathway in Jarcut-NFAT-luciferase-CD16 cells, which in turn led to an increase in luciferase expression levels. The ADCC activity of anti-claudin 18.2 antibodies was evaluated by detecting the luciferase expression level of Jarcut-NFAT-luciferase-CD16 in effector cells under the action of test antibodies (chimeric antibodies 1B6, 1E7) at various concentrations (100 μg / mL, 20 μg / mL, 4 μg / mL, 0.8 μg / mL, 0.16 μg / mL, 0.032 μg / mL, 0.0064 μg / mL, 0.00128 μg / mL, 0.000256 μg / mL, 0.0000512 μg / mL) and the control antibody IMAB362. The results are shown in Figure 11. In Figure 11, the EC50 at the half-peak concentration reflected the ADCC activity of the antibody. The smaller the EC50 at the half-peak concentration, the stronger the ADCC activity of the antibody. The experimental results showed that in target cells BXPC-3-claudin 18.2, as antibody concentrations increased, the mean values of the test antibodies (chimeric antibodies 1B6, 1E7) and the control antibody IMAB362 gradually increased until they reached a plateau and then halfway to the peak concentration. The half-peak concentrations (EC50) were 0.002114 μg / mL, 0.002698 μg / mL, and 0.003450 μg / mL, respectively.In the target cell Capan-1-claudin 18.2, the mean values of the test antibodies (1B6, 1E7) and the control antibody IMAB362 gradually increased with increasing antibody concentration until reaching a plateau, with half-peak concentrations (EC50) of 0.002676 μg / mL, 0.002634 μg / mL, and 0.003482 μg / mL, respectively. In the target cell SK-GT-claudin 18.2, the mean values of the test antibodies (chimeric antibodies 1B6, 1E7) and the control antibody IMAB362 gradually increased with increasing antibody concentration until reaching a plateau, with half-peak concentrations (EC50) of 0.004466 μg / mL, 0.007070 μg / mL, and 0.009061 μg / mL, respectively. It can be seen that the ADCC activity of the tested antibodies 1B6 and 1E7 was better than that of the control antibody IMAB362. [Examples]
[0154] Detection of CDC activity of anti-claudin 18.2 chimeric antibodies In this example, the CDC activity of anti-claudin 18.2 antibodies was evaluated by detecting the cell viability of target cells KATOIII-3-claudin 18.2 using the CCK8 method under the action of test antibodies (chimeric antibodies 1B6, 1E7) at various concentrations (90 μg / mL, 30 μg / mL, 10 μg / mL, 3.33 μg / mL, 1.11 μg / mL, 0.37 μg / mL, 0.123 μg / mL, 0.041 μg / mL) and the control antibody IMAB362. The results are shown in Figure 12. In Figure 12, the OD450 value reflected cell viability. The lower the OD450 value, the worse the cell viability. The IC50 at half-inhibitory concentration reflected the CDC activity of the antibody. The lower the IC50 at half-inhibitory concentration, the stronger the CDC activity of the antibody. The experimental results showed that as antibody concentrations increased, the OD450 values of the test antibodies (chimeric antibodies 1B6 and 1E7) and the control antibody IMAB362 gradually decreased until they approached zero. The IC50 values at half-inhibitory concentrations were 2.656 μg / mL, 1.567 μg / mL, and 4.889 μg / mL, respectively. This indicates that the CDC activity of the tested antibodies 1B6 and 1E7 was better than that of the control antibody IMAB362. [Examples]
[0155] Antitumor efficacy study of anti-claudin 18.2 antibody in subcutaneous xenograft tumors To evaluate the antitumor efficacy of anti-claudin 18.2 antibodies in mice, the antitumor efficacy of antibodies 1E7 and 1B6 was assessed using a BXPC3-18.2 subcutaneous xenograft tumor model. Logarithmically growing human pancreatic cancer cells BXPC3-18.2 were collected and centrifuged. After counting the cells, the cell density was adjusted to approximately 5.0 using a mixture of serum-free RPMI-1640 medium and Matrigel (1:1 ratio). * The concentration was adjusted to 107 / mL. A volume of 0.1 mL / mouse was injected subcutaneously into the dorsal cavity of nude mice. The average tumor volume was approximately 100 mm². 3 When the target was reached, the drugs were administered to mice in randomized groups. The drugs were administered alternately intravenously and intraperitoneally. IMAB362, chimeric antibody 1E7, and 1B6 were administered at 10 mg / kg. Each mouse received 10 uL / g for 6 weeks, twice a week for the first 3 weeks and once a week for the following 3 weeks. Starting from day 0 of administration, tumor size and mouse body weight were measured twice a week to calculate the trend of changes in tumor volume and body weight. Tumor growth inhibition rate (TGI) was used as the evaluation index. (TGI)% = [1-T / C] × 100%, where T and C were tumor volumes at the end of the experiment. Statistical analysis was performed using SPSS 16.0 software. One-way analysis of variance (one-way ANOVA) was used for comparisons between groups. P<0.05( * ) showed statistical significance.
[0156] The experimental results are shown in Figures 13 and 14. Antibodies IMAB362, 1E7, and 1B6 all exhibited specific inhibitory effects on tumor volume in the BXPC3-18.2 subcutaneous xenograft tumor model. Antibodies IMAB362 and 1B6 had the same inhibitory effect on tumor growth. TGI was 36-39%. Chimeric antibody 1E7 showed a better inhibitory effect on BXPC3-18.2 tumor growth, with a TGI of 51%. The difference was statistically significant compared to the control group. Antibodies IMAB362, 1B6, and 1E7 had no effect on weight gain in tumor-bearing mice.
[0157] Throughout this specification, any reference to “embodiment,” “partial embodiment,” “one embodiment,” “another embodiment,” “example,” “specific example,” or “partial example” means that any particular feature, structure, material, or characteristic described in relation to an embodiment or example is included in at least one embodiment or example of this disclosure. Therefore, the occurrence of the above terms throughout this specification does not necessarily refer to the same embodiment or example of this disclosure. Furthermore, specific features, structures, materials, or characteristics may be combined in any suitable manner within one or more embodiments or examples. Furthermore, those skilled in the art can incorporate and combine various embodiments, examples, or their features, provided they do not conflict with each other.
[0158] While explanatory embodiments have been shown and described, those skilled in the art will understand that the above embodiments should not be construed as limiting the disclosure, and that variations, substitutions, and modifications can be made to the embodiments without departing from the spirit, principles, and scope of the disclosure.
Claims
1. CDR sequences of the light chain variable region shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9; CDR sequences of the heavy chain variable regions shown in SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12 An antibody or antigen-binding fragment thereof capable of recognizing CLDN18.2, comprising a CDR sequence selected from at least one of the following amino acid sequences or an amino acid sequence having at least 95% identity thereto:
2. The antibody, the CDR1, CDR2, and CDR3 sequences of the light chain variable region shown in SEQ ID NOs: 1, 2, and 3, respectively, or amino acid sequences having at least 95% identity to SEQ ID NOs: 1, 2, and 3; or The CDR1, CDR2, and CDR3 sequences of the light chain variable region shown in SEQ ID NOs: 7, 8, and 9, respectively, or amino acid sequences having at least 95% identity to SEQ ID NOs: 7, 8, and 9 and / or The CDR1, CDR2, and CDR3 sequences of the heavy chain variable region shown in SEQ ID NOs: 4, 5, and 6, respectively, or amino acid sequences having at least 95% identity to SEQ ID NOs: 4, 5, and 6; or The CDR1, CDR2, and CDR3 sequences of the heavy chain variable region shown in SEQ ID NOs: 10, 11, and 12, respectively, or amino acid sequences having at least 95% identity with SEQ ID NOs: 10, 11, and 12 The antibody or antigen-binding fragment thereof of claim 1,
3. The antibody or antigen-binding fragment thereof described in claim 1, wherein, compared with peptide E, the antibody or antigen-binding fragment uses peptide A as a dominant epitope that specifically recognizes CLDN18.2, and the sequence of peptide E has the amino acid sequence of SEQ ID NO: 14, and the sequence of peptide A has the amino acid sequence of SEQ ID NO:
13.
4. At least one of a heavy chain framework region sequence and a light chain framework region sequence and wherein at least a portion of at least one of the heavy chain framework region sequences and the light chain framework region sequences is derived from at least one of a murine antibody, a human antibody, a primate antibody, or a mutant thereof.
5. The antibody has a light chain variable region having the amino acid sequence shown in SEQ ID NO: 15 or SEQ ID NO:
16. and / or The antibody has a heavy chain variable region having the amino acid sequence shown in SEQ ID NO: 17 or SEQ ID NO:
18. Optionally, the antibody has a light chain variable region having the amino acid sequence set forth in SEQ ID NO: 15 and a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:
17. Optionally, the antibody has a light chain variable region having the amino acid sequence set forth in SEQ ID NO: 16 and a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO:
18. The antibody or antigen-binding fragment thereof described in claim 1.
6. the antibody comprises at least one of a heavy chain constant region and a light chain constant region, wherein at least a portion of at least one of the heavy chain constant region and the light chain constant region is derived from at least one of a murine antibody, a human antibody, a primate antibody, or a mutant thereof; Optionally, both the light chain constant region and the heavy chain constant region of the antibody are derived from a murine IgG antibody or mutant thereof. The antibody or antigen-binding fragment thereof described in claim 1.
7. and / or having a light chain having the amino acid sequence shown in SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 32, or SEQ ID NO:
34. having a heavy chain having the amino acid sequence shown in SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:31, or SEQ ID NO:33; The antibody or antigen-binding fragment thereof described in claim 1.
8. the antibody is a single chain antibody, a chimeric antibody, a multimeric antibody, or a CDR-grafted antibody; Optionally, the antigen-binding fragment comprises at least one of a Fab fragment, a (Fab)2 fragment, an scFv-Fc fusion protein, an scFv-Fv fusion protein, an Fv fragment, and a minimal recognition unit. The antibody or antigen-binding fragment thereof described in claim 1.
9. 9. The antibody or antigen-binding fragment thereof of claim 8, wherein the antibody is a single-chain antibody, and the single-chain antibody has the amino acid sequence shown in SEQ ID NO: 23 or SEQ ID NO:
24.
10. A chimeric antigen receptor comprising an extracellular domain comprising a heavy chain variable domain and a light chain variable domain of a single chain antibody, wherein the light chain variable domain and the heavy chain variable domain are determined according to the antibody or antigen-binding fragment thereof according to any one of claims 1 to 9.
11. the chimeric antigen receptor further comprises a transmembrane domain and an intracellular domain, the transmembrane domain comprising a CD8 transmembrane domain and the intracellular domain comprising ICOS, 4-1BB, and an intracellular segment of the CD3 zeta chain; optionally, the N-terminus of the intracellular segment of ICOS is connected to the C-terminus of the CD8 transmembrane domain, the C-terminus of the intracellular segment of ICOS is connected to the N-terminus of the intracellular segment of 4-1BB, and the C-terminus of the intracellular segment of 4-1BB is connected to the N-terminus of the CD3 zeta chain; The chimeric antigen receptor of claim 10.
12. 11. A nucleic acid molecule encoding an antibody or antigen-binding fragment thereof according to any one of claims 1 to 9, or a chimeric antigen receptor according to claim 10, which is optionally DNA.
13. An expression vector comprising the nucleic acid molecule of claim 12, which is optionally a eukaryotic expression vector or virus, and optionally the virus is a lentivirus.
14. A recombinant cell comprising the nucleic acid molecule of claim 12 or the expression vector of claim 13, wherein the recombinant cell expresses the antibody or antigen-binding fragment thereof of any one of claims 1 to 9 or the chimeric antigen receptor of claim 10, the antibody or antigen-binding fragment thereof being encoded by the nucleic acid molecule. Optionally, the cell is a eukaryotic cell, and optionally a mammalian cell; Recombinant cells.
15. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 9.
12. The chimeric antigen receptor of claim 10 or 11. The nucleic acid molecule of claim 12. An expression vector according to claim 13, or The recombinant cell of claim 14.
23. A pharmaceutical composition comprising:
16. 16. An antibody or antigen-binding fragment thereof according to any one of claims 1 to 9, a chimeric antigen receptor according to claim 10 or 11, a nucleic acid molecule according to claim 12, an expression vector according to claim 13, a recombinant cell according to claim 14, or a pharmaceutical composition according to claim 15, for use in diagnosing, treating, or preventing a CLDN18.2-related disease in a subject.
17. The antibody or antigen-binding fragment thereof, chimeric antigen receptor, immune cell, nucleic acid molecule, expression vector, recombinant cell, or pharmaceutical composition of claim 16, wherein the CLDN18.2-associated disease comprises a tumor, optionally wherein the tumor comprises a solid tumor expressing CLDN18.2, and optionally wherein the solid tumor comprises gastric cancer, pancreatic cancer, esophageal cancer, and lung cancer.
